Management of chronic obstructive pulmonary disease: Insights into patient profile – Use of inhaled corticosteroids/long-acting β2-Agonists or long-acting β2-agonists/long-acting muscarinic antagonists
The noncommunicable chronic obstructive pulmonary disease (COPD) ranks among the top five leading causes of death worldwide. It is a preventable chronic disease that has become a major public health concern globally, as well as in India. To improve the pharmacotherapeutic management of COPD and to i...
Main Authors: | Nevin Kishore, Saibal Moitra, Mrinal Sircar |
---|---|
Format: | Article |
Language: | English |
Published: |
Jaypee Brothers Medical Publisher
2020-01-01
|
Series: | Indian Journal of Respiratory Care |
Subjects: | |
Online Access: | http://www.ijrconline.org/article.asp?issn=2277-9019;year=2020;volume=9;issue=2;spage=162;epage=170;aulast=Kishore |
Similar Items
-
Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
by: Donohue JF, et al.
Published: (2019-12-01) -
The effect of combining an inhaled corticosteroid and a long-acting muscarinic antagonist on human airway epithelial cells in vitro
by: Maria Gabriella Matera, et al.
Published: (2024-02-01) -
Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD
by: Bishwakarma R, et al.
Published: (2017-01-01) -
NEW FIXED COMBINATION OF LONG-ACTING ANTICHOLINERGIC GLYCOPYRRONIUM BROMIDE AND β2-AGONIST OF INDACATEROL: PROSPECTS OF COBD THERAPY
by: S. N. AVDEEV
Published: (2016-12-01) -
Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids
by: Liao PA, et al.
Published: (2023-04-01)